ResearcherNew York UniversityActive in the last 2 years
Joshua Leinwand
Matched on ORCID iD 0000-0003-3759-0764; OpenAlex author ID A5029693895. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers
Papers 7
- Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18915-0↗
- ASO Visual Abstract: Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19157-4↗
- Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Co-author DOI 10.1038/s41388-023-02606-9↗
- BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Co-author DOI 10.1038/s41388-022-02425-4↗
- Regulation and modulation of antitumor immunity in pancreatic cancer. Co-author DOI 10.1038/s41590-020-0761-y↗
- Microbes as biomarkers and targets in pancreatic cancer. Co-author DOI 10.1038/s41571-019-0276-3↗
- RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.10.006↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- George Miller · 5 shared papers, 2018–2023 · strength 0.73
- Paper Regulation and modulation of antitumor immunity in pancreatic cancer. DOI 10.1038/s41590-020-0761-y↗
- Paper Microbes as biomarkers and targets in pancreatic cancer. DOI 10.1038/s41571-019-0276-3↗
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Neha L. Lad · 2 shared papers, 2026 · strength 0.50
- Paper Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. DOI 10.1245/s10434-025-18915-0↗
- Paper ASO Visual Abstract: Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients w… DOI 10.1245/s10434-026-19157-4↗
- Umut Sarpel · 2 shared papers, 2026 · strength 0.50
- Paper Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. DOI 10.1245/s10434-025-18915-0↗
- Paper ASO Visual Abstract: Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients w… DOI 10.1245/s10434-026-19157-4↗
- Judy Li · 2 shared papers, 2026 · strength 0.50
- Paper Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. DOI 10.1245/s10434-025-18915-0↗
- Paper ASO Visual Abstract: Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients w… DOI 10.1245/s10434-026-19157-4↗
- Camilo Correa‐Gallego · 2 shared papers, 2026 · strength 0.50
- Paper Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. DOI 10.1245/s10434-025-18915-0↗
- Paper ASO Visual Abstract: Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients w… DOI 10.1245/s10434-026-19157-4↗
- Noah A. Cohen · 2 shared papers, 2026 · strength 0.50
- Paper Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. DOI 10.1245/s10434-025-18915-0↗
- Paper ASO Visual Abstract: Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients w… DOI 10.1245/s10434-026-19157-4↗
- Deirdre Jill Cohen · 3 shared papers, 2018–2023 · strength 0.29
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Paper RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.10.006↗
- Berk Aykut · 3 shared papers, 2018–2023 · strength 0.29
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Paper RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.10.006↗
- Wei Wang · 3 shared papers, 2018–2023 · strength 0.29
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Paper RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.10.006↗
- Gregor Werba · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Brian E. Diskin · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastati… DOI 10.1038/s41388-023-02606-9↗
- Paper BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary p… DOI 10.1038/s41388-022-02425-4↗
- Emma Kurz · 1 shared paper, 2018 · strength 0.05
- Fei Li · 1 shared paper, 2018 · strength 0.05
- Philip A. Harris · 1 shared paper, 2018 · strength 0.05
- Atsuo Ochi · 1 shared paper, 2018 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.